{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:49:19Z","timestamp":1793166559675,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The 2015 International Parkinson and\n                    <jats:italic>Movement Disorder<\/jats:italic>\n                    Society (MDS) Diagnostic criteria for Parkinson Disease are based on expert consensus opinion and defines core motor features, \u2018Absolute Exclusion Criteria\u2019 and a balance of \u2018Supportive Criteria\u2019 and \u2018Red Flags\u2019. To assess validity of each criterion in pathologically-confirmed cases, a scoping literature review between 1988-2024 using search terms for clinicopathological PD and atypical parkinsonian disorders identified 28 articles. Supportive criteria were higher in PD, with excellent levodopa response and rest tremor most useful. Absolute exclusion criteria and red flags were present more often in atypical parkinsonian disorders. However, supranuclear gaze palsy, rapid progression of gait impairment to wheelchair requirement and bilateral symptoms were reported in &gt;5% PD. Data was limited by few appropriate pathological studies with sufficient clinical data; challenges in applying highly-specific definitions to retrospective studies and likely co-pathologies. This review provides empiric data to support some items of the MDS Criteria with future potential refinement.\n                  <\/jats:p>","DOI":"10.1038\/s41531-025-01206-6","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T10:07:40Z","timestamp":1765620460000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Revisiting the 2015 MDS diagnostic criteria for Parkinson disease: insights from autopsy-confirmed cases"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7568-1645","authenticated-orcid":false,"given":"Susan H.","family":"Fox","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1356-4919","authenticated-orcid":false,"given":"Daniel G.","family":"Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6468-4734","authenticated-orcid":false,"given":"Ronald B.","family":"Postuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6901-2064","authenticated-orcid":false,"given":"Roongroj","family":"Bhidayasiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0808-0116","authenticated-orcid":false,"given":"Francisco","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3841-5511","authenticated-orcid":false,"given":"Gabor G.","family":"Kovacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-9271","authenticated-orcid":false,"given":"Regina","family":"Katzenschlager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6407-1199","authenticated-orcid":false,"given":"Claudia","family":"Trenkwalder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,13]]},"reference":[{"key":"1206_CR1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","volume":"23","author":"GU Hoglinger","year":"2024","unstructured":"Hoglinger, G. U. et al. A biological classification of Parkinson\u2019s disease: the SynNeurGe research diagnostic criteria. Lancet Neurol. 23, 191\u2013204 (2024).","journal-title":"Lancet Neurol."},{"key":"1206_CR2","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","volume":"23","author":"T Simuni","year":"2024","unstructured":"Simuni, T. et al. A biological definition of neuronal alpha-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 23, 178\u2013190 (2024).","journal-title":"Lancet Neurol."},{"key":"1206_CR3","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/mds.29683","volume":"39","author":"F Cardoso","year":"2024","unstructured":"Cardoso, F. et al. A statement of the MDS on biological definition, staging, and classification of Parkinson\u2019s disease. Mov. Disord. 39, 259\u2013266 (2024).","journal-title":"Mov. Disord."},{"key":"1206_CR4","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1136\/jnnp.51.6.745","volume":"51","author":"WR Gibb","year":"1988","unstructured":"Gibb, W. R. & Lees, A. J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson\u2019s disease. J. Neurol. Neurosurg. Psychiatry 51, 745\u2013752 (1988).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1206_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1365-2990.1989.tb01147.x","volume":"15","author":"WR Gibb","year":"1989","unstructured":"Gibb, W. R. & Lees, A. J. The significance of the Lewy body in the diagnosis of idiopathic Parkinson\u2019s disease. Neuropathol. Appl Neurobiol. 15, 27\u201344 (1989).","journal-title":"Neuropathol. Appl Neurobiol."},{"key":"1206_CR6","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/mds.10459","volume":"18","author":"I Litvan","year":"2003","unstructured":"Litvan, I. et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov. Disord. 18, 467\u2013486 (2003).","journal-title":"Mov. Disord."},{"key":"1206_CR7","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov. Disord. 30, 1591\u20131601 (2015).","journal-title":"Mov. Disord."},{"key":"1206_CR8","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1002\/mds.27362","volume":"33","author":"RB Postuma","year":"2018","unstructured":"Postuma, R. B. et al. Validation of the MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov. Disord. 33, 1601\u20131608 (2018).","journal-title":"Mov. Disord."},{"key":"1206_CR9","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/mds.29317","volume":"38","author":"S Virameteekul","year":"2023","unstructured":"Virameteekul, S., Revesz, T., Jaunmuktane, Z., Warner, T. T. & De Pablo-Fernandez, E. Clinical diagnostic accuracy of Parkinson\u2019s Disease: where do we stand?. Mov. Disord. 38, 558\u2013566 (2023).","journal-title":"Mov. Disord."},{"key":"1206_CR10","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1002\/mds.28406","volume":"36","author":"WRWM Martin","year":"2021","unstructured":"Martin, W. R. W. M. et al. Is Levodopa response a valid indicator of Parkinson\u2019s disease?. Mov. Disord. 36, 948\u2013954 (2021).","journal-title":"Mov. Disord."},{"key":"1206_CR11","doi-asserted-by":"publisher","first-page":"E414","DOI":"10.1212\/CPJ.0000000000001016","volume":"11","author":"CHB Adler","year":"2021","unstructured":"Adler, C. H. B. et al. Clinical diagnostic accuracy of early\/advanced Parkinson disease: an updated clinicopathologic study. Neurol. Clin. Pract. 11, E414\u2013E421 (2021).","journal-title":"Neurol. Clin. Pract."},{"key":"1206_CR12","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209453","volume":"102","author":"A Hastings","year":"2024","unstructured":"Hastings, A. et al. Neuropathologic validation and diagnostic accuracy of presynaptic dopaminergic imaging in the diagnosis of Parkinsonism. Neurology 102, e209453 (2024).","journal-title":"Neurology"},{"key":"1206_CR13","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1007\/s10072-023-06628-9","volume":"44","author":"VC Constantinides","year":"2023","unstructured":"Constantinides, V. C. et al. Dopamine transporter SPECT imaging in Parkinson\u2019s disease and atypical Parkinsonism: a study of 137 patients. Neurol. Sci. 44, 1613\u20131623 (2023).","journal-title":"Neurol. Sci."},{"key":"1206_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-020-00914-9","volume":"8","author":"HH Geut","year":"2020","unstructured":"Geut, H. H. et al. Neuropathological correlates of parkinsonian disorders in a large Dutch autopsy series. Acta Neuropathol. Commun. 8, 39 (2020).","journal-title":"Acta Neuropathol. Commun."},{"key":"1206_CR15","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.parkreldis.2017.02.027","volume":"38","author":"WRWH Martin","year":"2017","unstructured":"Martin, W. R. W. H., Racette, J., Cairns, B. A. & Perlmutter, N. J. S. J. S. Pathologic correlates of supranuclear gaze palsy with parkinsonism. Parkinsonism Relat. Disord. 38, 68\u201371 (2017).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1206_CR16","doi-asserted-by":"publisher","first-page":"II1","DOI":"10.1007\/BF03161075","volume":"246","author":"IG Litvan","year":"1999","unstructured":"Litvan, I. G. et al. Clinical features differentiating patients with postmortem confirmed progressive supranuclear palsy and corticobasal degeneration. J. Neurol. 246, II1\u2013II5 (1999).","journal-title":"J. Neurol."},{"key":"1206_CR17","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1002\/ana.27190","volume":"97","author":"L di Biase","year":"2025","unstructured":"di Biase, L., Pecoraro, P. M. & Di Lazzaro, V. Validating the accuracy of Parkinson\u2019s disease clinical diagnosis: a UK Brain Bank case-control study. Ann. Neurol. 97, 1110\u20131121 (2025).","journal-title":"Ann. Neurol."},{"key":"1206_CR18","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00401-020-02255-2","volume":"141","author":"J Attems","year":"2021","unstructured":"Attems, J. et al. Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study. Acta Neuropathol. 141, 159\u2013172 (2021).","journal-title":"Acta Neuropathol."},{"key":"1206_CR19","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1093\/brain\/awz099","volume":"142","author":"PT Nelson","year":"2019","unstructured":"Nelson, P. T. et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain 142, 1503\u20131527 (2019).","journal-title":"Brain"},{"key":"1206_CR20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00401-020-02158-2","volume":"140","author":"GG Kovacs","year":"2020","unstructured":"Kovacs, G. G. et al. Distribution patterns of tau pathology in progressive supranuclear palsy. Acta Neuropathol. 140, 99\u2013119 (2020).","journal-title":"Acta Neuropathol."},{"key":"1206_CR21","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1017\/cjn.2022.34","volume":"50","author":"SL Forrest","year":"2023","unstructured":"Forrest, S. L. & Kovacs, G. G. Current concepts of mixed pathologies in neurodegenerative diseases. Can. J. Neurol. Sci. 50, 329\u2013345 (2023).","journal-title":"Can. J. Neurol. Sci."},{"key":"1206_CR22","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.pathol.2024.10.006","volume":"57","author":"SL Forrest","year":"2025","unstructured":"Forrest, S. L. & Kovacs, G. G. Current concepts and molecular pathology of neurodegenerative diseases. Pathology 57, 178\u2013190 (2025).","journal-title":"Pathology"},{"key":"1206_CR23","doi-asserted-by":"publisher","first-page":"E1821","DOI":"10.1212\/WNL.0000000000007315","volume":"92","author":"ASY Buchman","year":"2019","unstructured":"Buchman, A. S. Y. et al. Progressive parkinsonism in older adults is related to the burden of mixed brain pathologies. Neurology 92, E1821\u2013E1830 (2019).","journal-title":"Neurology"},{"key":"1206_CR24","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1093\/brain\/awad059","volume":"146","author":"JLX Robinson","year":"2023","unstructured":"Robinson, J. L. X. et al. Pathological combinations in neurodegenerative disease are heterogeneous and disease-associated. Brain 146, 2557\u20132569 (2023).","journal-title":"Brain"},{"key":"1206_CR25","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1002\/mds.27431","volume":"33","author":"D Berg","year":"2018","unstructured":"Berg, D. et al. Movement disorder society criteria for clinically established early Parkinson\u2019s disease. Mov. Disord. 33, 1643\u20131646 (2018).","journal-title":"Mov. Disord."},{"key":"1206_CR26","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1093\/brain\/awf080","volume":"125","author":"AJ Hughes","year":"2002","unstructured":"Hughes, A. J., Daniel, S. E., Ben-Shlomo, Y. & Lees, A. J. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125, 861\u2013870 (2002).","journal-title":"Brain"},{"key":"1206_CR27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1017\/cjn.2015.244","volume":"43","author":"LWR Ferguson","year":"2016","unstructured":"Ferguson, L. W. R., Rajput, A. H. & Rajput, A. Early-onset vs. Late-onset Parkinson\u2019s disease: a clinical-pathological study. Can. J. Neurol. Sci. 43, 113\u2013119 (2016).","journal-title":"Can. J. Neurol. Sci."},{"key":"1206_CR28","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1001\/jamaneurol.2018.4377","volume":"76","author":"EL De Pablo-Fern\u00e1ndez","year":"2019","unstructured":"De Pablo-Fern\u00e1ndez, E. L., Holton, J. L., Lees, A. J. & Warner, T. T Prognosis and neuropathologic correlation of clinical subtypes of parkinson disease. JAMA Neurol. 76, 470\u2013479 (2019).","journal-title":"JAMA Neurol."},{"key":"1206_CR29","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes, A. J., Daniel, S. E., Kilford, L. & Lees, A. J. Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55, 181\u2013184 (1992).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1206_CR30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.parkreldis.2018.07.015","volume":"57","author":"KA Jellinger","year":"2018","unstructured":"Jellinger, K. A. Very old onset parkinsonism: a clinical-pathological study. Parkinsonism Relat. Disord. 57, 39\u201343 (2018).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1206_CR31","doi-asserted-by":"crossref","unstructured":"Wenning, Y. et al. What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson\u2019s disease?. J. Neurol. Neurosurg. Psychiatry 68, 434\u2013440 (2000).","DOI":"10.1136\/jnnp.68.4.434"},{"key":"1206_CR32","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1093\/brain\/awab017","volume":"144","author":"YT Miki","year":"2021","unstructured":"Miki, Y. T. et al. Identification of multiple system atrophy mimicking Parkinson\u2019s disease or progressive supranuclear palsy. Brain 144, 1138\u20131151 (2021).","journal-title":"Brain"},{"key":"1206_CR33","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2169\/internalmedicine.4836-20","volume":"60","author":"CT Ishida","year":"2021","unstructured":"Ishida, C. T., Kato-Motozaki, K., Tagami, Y. & Komai, A. K. Effectiveness of levodopa in patients with multiple system atrophy and associated clinicopathological features. Intern. Med. 60, 367\u2013372 (2021).","journal-title":"Intern. Med."},{"key":"1206_CR34","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1136\/jnnp.55.11.1009","volume":"55","author":"AJC Hughes","year":"1992","unstructured":"Hughes, A. J. C., Kleedorfer, C., Daniel, B. & Lees, S. E. A. J. The dopaminergic response in multiple system atrophy. J. Neurol. Neurosurg. Psychiatry 55, 1009\u20131013 (1992).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1206_CR35","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/mds.870120203","volume":"12","author":"GK Wenning","year":"1997","unstructured":"Wenning, G. K., Tison, F., Ben Shlomo, Y., Daniel, S. E. & Quinn, N. P. Multiple system atrophy: a review of 203 pathologically proven cases. Mov. Disord. 12, 133\u2013147 (1997).","journal-title":"Mov. Disord."},{"key":"1206_CR36","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/mds.25220","volume":"28","author":"MK Selikhova","year":"2013","unstructured":"Selikhova, M. K., Revesz, P. A., Holton, T. & Lees, J. L. A. J. Neuropathological findings in benign tremulous Parkinsonism. Mov. Disord. 28, 145\u2013152 (2013).","journal-title":"Mov. Disord."},{"key":"1206_CR37","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1212\/WNL.42.6.1142","volume":"42","author":"AJB-S Hughes","year":"1992","unstructured":"Hughes, A. J. B.-S., Daniel, Y. & Lees, S. E. A. J. What features improve the accuracy of clinical diagnosis in Parkinson\u2019s disease: a clinicopathologic study. Neurology 42, 1142\u20131146 (1992).","journal-title":"Neurology"},{"key":"1206_CR38","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1212\/WNL.0b013e3181ae7af1","volume":"73","author":"AHV Rajput","year":"2009","unstructured":"Rajput, A. H. V., Rajput, A., Robinson, M. L. & Rajput, C. A. A. Course in parkinson disease subtypes: a 39-year clinicopathologic study. Neurology 73, 206\u2013212 (2009).","journal-title":"Neurology"},{"key":"1206_CR39","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1002\/mds.26346","volume":"30","author":"TM Virmani","year":"2015","unstructured":"Virmani, T. M., Vonsattel, C. B. & Fahn, J. P. S. Clinicopathological characteristics of freezing of gait in autopsy-confirmed Parkinson\u2019s disease. Mov. Disord. 30, 1874\u20131884 (2015).","journal-title":"Mov. Disord."},{"key":"1206_CR40","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1212\/WNL.43.4.829","volume":"43","author":"AH Rajput","year":"1993","unstructured":"Rajput, A. H., Pahwa, R., Pahwa, P. & Rajput, A. Prognostic significance of the onset mode in parkinsonism. Neurology 43, 829\u2013830 (1993).","journal-title":"Neurology"},{"key":"1206_CR41","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1212\/WNL.0000000000001807","volume":"85","author":"SA Koga","year":"2015","unstructured":"Koga, S. A. et al. When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients. Neurology 85, 404\u2013412 (2015).","journal-title":"Neurology"},{"key":"1206_CR42","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1001\/archneur.1997.00550200007003","volume":"54","author":"IG Litvan","year":"1997","unstructured":"Litvan, I. G. et al. What is the accuracy of the clinical diagnosis of multiple system atrophy?: A clinicopathologic study. Arch. Neurol. 54, 937\u2013944 (1997).","journal-title":"Arch. Neurol."},{"key":"1206_CR43","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1093\/brain\/awz189","volume":"142","author":"YF Miki","year":"2019","unstructured":"Miki, Y. F. et al. Improving diagnostic accuracy of multiple system atrophy: a clinicopathological study. Brain 142, 2813\u20132827 (2019).","journal-title":"Brain"},{"key":"1206_CR44","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1001\/archneur.1995.00540270090024","volume":"52","author":"CA Colosimo","year":"1995","unstructured":"Colosimo, C. A., Hughes, A., de Bruin, A. J. & Lees, V. M. A. J. Some specific clinical features differentiate multiple system atrophy (striatonigral variety) from Parkinson\u2019s disease. Arch. Neurol. 52, 294\u2013298 (1995).","journal-title":"Arch. Neurol."},{"key":"1206_CR45","doi-asserted-by":"crossref","unstructured":"M\u00fcller, J. et al. Freezing of gait in postmortem-confirmed atypical parkinsonism. Mov. Disord. 17, 1041\u20131045 (2002).","DOI":"10.1002\/mds.10234"},{"key":"1206_CR46","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1136\/jnnp.67.5.620","volume":"67","author":"GKS Wenning","year":"1999","unstructured":"Wenning, G. K. S. et al. Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study. J. Neurol. Neurosurg. Psychiatry 67, 620\u2013623 (1999).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1206_CR47","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1002\/mds.25927","volume":"29","author":"JJS Figueroa","year":"2014","unstructured":"Figueroa, J. J. S. et al. Multiple system atrophy: prognostic indicators of survival. Mov. Disord. 29, 1151\u20131157 (2014).","journal-title":"Mov. Disord."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01206-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01206-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01206-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T17:01:51Z","timestamp":1767027711000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01206-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,13]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1206"],"URL":"https:\/\/doi.org\/10.1038\/s41531-025-01206-6","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,13]]},"assertion":[{"value":"4 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.H.F. has received clinic support from the Edmond J Safra Foundation for Parkinson Research; Parkinson Foundation and UHN Foundation. Research Funding from Michael J Fox Foundation for Parkinson Research, NIH (Dystonia Coalition); Parkinson Canada; Weston Foundation. Honoraria from the International Parkinson and Movement Disorder Society. Site PI for Clinical Trials for Alexion, Biotie, Consultancy\/Speaker fees from Abbvie, Lundbeck, Sunovion; Royalties from Oxford University Press Daniel Di Luca reported no financial disclosures. Ron Postuma. is supported by grants from FRQ-S, CIHR, the Michael J. Fox Foundation, the Webster Foundation, Roche, and the NIH; R.P. reports personal fees from Abbvie, Curasen, Novartis, Vanqua, Merck, Vaxxinity, Bristol Myers Squibb, Clinilabs, Epic, Regeneron, Helicon, and the International Parkinson and Movement Disorders Society, outside the submitted work.Roongroj Bhidayasiri has received grants from the following agencies: the Thailand Science Research and Innovation (TSRI, Programme Management Unit for Competitiveness, C01F670185), the National Economic and Social Development Council of Thailand, Thailand Centre of Excellence for Life Sciences (TC (ERP) 31\/2568), the National Research Council of Thailand (N42A680591, N35E680087), and Chulalongkorn University (CE68_028_3000_004). He is also supported by the Royal Society of Thailand, has provided consultancy services, and has received honoraria and lecture fees from industries such as Britannia, Ipsen, Teva-Lundbeck, and Mitsubishi-Tanabe. Bhidayasiri holds patents for various innovations, including a laser-guided walking stick, a portable tremor device, technology for monitoring during the night (NIGHT-Recorder), an electronic diary for Parkinson\u2019s disease symptoms, as well as the Parkinson insole and shoe, and anti-choking mugs. Furthermore, his copyrighted works comprise the mobile application for screening Parkinson\u2019s disease (Check PD), a Parkinson\u2019s mascot, a daily activity diary for Parkinson\u2019s, creative dopamine-themed lyrics, and educational video content focusing on common nighttime and gastrointestinal symptoms associated with Parkinson\u2019s disease. Franciso Cardoso reported speaker roles for Torrent and Bial e Teva and the advisory board for Knight e Ventus.Gabor Kovacs reports personal fees from Parexel and Mitsubishi-Tanabe; funding from Rossy Family Foundation, from Edmond Safra Foundation, grants from Krembil Foundation, MSA Coalition, MJ Fox Foundation, Parkinson Canada, NIH, Canada Foundation for Innovation, and Ontario Research Fund outside the submitted work; in addition, GGK has a shared patent for 5G4 Synuclein antibody and a pending patent for Diagnostic assays for movement disorders (18\/537,455), and received royalties from Wiley, Cambridge, Taylor and Francis, and Elsevier publishers. Regina Katzenschlager has received personal fees, honoraria for consulting or speaking, or research grants from: AbbVie, Bial, Britannia, Ever Pharma, Merz, Neuroderm, Novartis, Stada, Supernus, UCB, ZambonClaudia Trenkwalder has received grants from DLR ERA Net-BRAVA Project, PPMI, Royalities from Thieme Publisher, PDSS-2 license fee, Consulting Fees from Abbvie, Bial, Boehringer, Roche, UCB, Convatec, Honoraria\/Speaker fees from Abbvie, Bial, Esteve, MDS, German Parkinson Society, European Academy of Neurology.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"360"}}